Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

 
• By Jessica Merrill
  
Time out hands
Bristol's TYK2 inhibitor failed a Phase II study in ulcerative colitis • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapeutic Category